REFERENCES
1. Mavrogenis AF, Karampikas V, Zikopoulos A, et al. Orthobiologics: a review. Int Orthop. 2023;47:1645-62.
2. Laver L, Filardo G, Sanchez M, et al; ESSKA‐ORBIT Group. The use of injectable orthobiologics for knee osteoarthritis: a European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma). Knee Surg Sports Traumatol Arthrosc. 2024;32:783-97.
3. Perucca Orfei C, Boffa A, Sourugeon Y, et al. Cell-based therapies have disease-modifying effects on osteoarthritis in animal models. A systematic review by the ESSKA orthobiologic initiative. Part 1: adipose tissue-derived cell-based injectable therapies. Knee Surg Sports Traumatol Arthrosc. 2023;31:641-55.
4. Boffa A, Perucca Orfei C, Sourugeon Y, et al. Cell-based therapies have disease-modifying effects on osteoarthritis in animal models. A systematic review by the ESSKA orthobiologic initiative. Part 2: bone marrow-derived cell-based injectable therapies. Knee Surg Sports Traumatol Arthrosc. 2023;31:3230-42.
5. Boffa A, Salerno M, Merli G, et al. Platelet-rich plasma injections induce disease-modifying effects in the treatment of osteoarthritis in animal models. Knee Surg Sports Traumatol Arthrosc. 2021;29:4100-21.
6. Rodeo SA. Orthobiologics: current status in 2023 and future outlook. J Am Acad Orthop Surg. 2023;31:604-13.
7. The use of injectable Orthobiologics for knee osteoarthritis: a formal ESSKA consensus Part 2 - cell-based therapy (CBT). Available from: https://cdn.ymaws.com/www.esska.org/resource/resmgr/docs/consensus_projects/2024_orbit_complete_report.pdf. [Last accessed on 24 Apr 2025].
9. Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6:1445-51.
10. Miclau K, Hambright WS, Huard J, Stoddart MJ, Bahney CS. Cellular expansion of MSCs: shifting the regenerative potential. Aging Cell. 2023;22:e13759.
11. Harrison-Brown M, Scholes C, Hafsi K, et al. Efficacy and safety of culture-expanded, mesenchymal stem/stromal cells for the treatment of knee osteoarthritis: a systematic review protocol. J Orthop Surg Res. 2019;14:34.
12. Ragni E, Perucca Orfei C, De Luca P, et al. Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease. Stem Cell Res Ther. 2020;11:165.
13. Ragni E, Perucca Orfei C, de Girolamo L. Secreted factors and extracellular vesicles account for the immunomodulatory and tissue regenerative properties of bone-marrow-derived mesenchymal stromal cells for osteoarthritis. Cells. 2022;11:3501.
14. Gstraunthaler G, Lindl T, van der Valk J. A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology. 2013;65:791-3.
15. Rowland AL, Burns ME, Levine GJ, Watts AE. Preparation technique affects recipient immune targeting of autologous mesenchymal stem cells. Front Vet Sci. 2021;8:724041.
16. Iudicone P, Fioravanti D, Bonanno G, et al. Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells. J Transl Med. 2014;12:28.
17. Aussel C, Busson E, Vantomme H, Peltzer J, Martinaud C. Quality assessment of a serum and xenofree medium for the expansion of human GMP-grade mesenchymal stromal cells. PeerJ. 2022;10:e13391.
18. Bui HTH, Nguyen LT, Than UTT. Influences of Xeno-free media on mesenchymal stem cell expansion for clinical application. Tissue Eng Regen Med. 2021;18:15-23.
19. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315-7.
20. Fitzgerald JC, Shaw G, Murphy JM, Barry F. Media matters: culture medium-dependent hypervariable phenotype of mesenchymal stromal cells. Stem Cell Res Ther. 2023;14:363.
21. Liu S, de Castro LF, Jin P, et al. Manufacturing differences affect human bone marrow stromal cell characteristics and function: comparison of production methods and products from multiple centers. Sci Rep. 2017;7:46731.
22. Giannasi C, Della Morte E, Cadelano F, et al. Boosting the therapeutic potential of cell secretome against osteoarthritis: comparison of cytokine-based priming strategies. Biomed Pharmacother. 2024;170:115970.
23. Ragni E, Colombini A, Viganò M, et al. Cartilage protective and immunomodulatory features of osteoarthritis synovial fluid-treated adipose-derived mesenchymal stem cells secreted factors and extracellular vesicles-embedded miRNAs. Cells. 2021;10:1072.
24. D’haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol Biol. 2012;822:261-72.
25. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638-46.
26. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015;43:W566-70.
27. Lipps C, Klein F, Wahlicht T, et al. Expansion of functional personalized cells with specific transgene combinations. Nat Commun. 2018;9:994.
28. Chou CH, Jain V, Gibson J, et al. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. Sci Rep. 2020;10:10868.
29. Chouaib B, Desoutter A, Cuisinier F, Collart-Dutilleul PY. Dental pulp stem cell conditioned medium enhance osteoblastic differentiation and bone regeneration. Stem Cell Rev Rep. 2025;21:477-90.
30. Su Y, Xu C, Cheng W, Zhao Y, Sui L, Zhao Y. Pretreated mesenchymal stem cells and their secretome: enhanced immunotherapeutic strategies. Int J Mol Sci. 2023;24:1277.
31. Bowles AC, Kouroupis D, Willman MA, Perucca Orfei C, Agarwal A, Correa D. Signature quality attributes of CD146+ mesenchymal stem/stromal cells correlate with high therapeutic and secretory potency. Stem Cells. 2020;38:1034-49.
32. Cheng NC, Tu YK, Lee NH, Young TH. Influence of human platelet lysate on extracellular matrix deposition and cellular characteristics in adipose-derived stem cell sheets. Front Cell Dev Biol. 2020;8:558354.
33. Gharibi B, Hughes FJ. Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. Stem Cells Transl Med. 2012;1:771-82.
34. Civinini R, Nistri L, Martini C, Redl B, Ristori G, Innocenti M. Growth factors in the treatment of early osteoarthritis. Clin Cases Miner Bone Metab. 2013;10:26-9.
35. Wen C, Xu L, Xu X, Wang D, Liang Y, Duan L. Insulin-like growth factor-1 in articular cartilage repair for osteoarthritis treatment. Arthritis Res Ther. 2021;23:277.
36. Su S, Grover J, Roughley PJ, et al. Expression of the tissue inhibitor of metalloproteinases (TIMP) gene family in normal and osteoarthritic joints. Rheumatol Int. 1999;18:183-91.
37. Deng ZH, Li YS, Gao X, Lei GH, Huard J. Bone morphogenetic proteins for articular cartilage regeneration. Osteoarthritis Cartilage. 2018;26:1153-61.
38. Luo W, Lin Z, Yuan Y, Wu Z, Zhong W, Liu Q. Osteopontin (OPN) alleviates the progression of osteoarthritis by promoting the anabolism of chondrocytes. Genes Dis. 2023;10:1714-25.
39. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med. 2009;58:29-40.
40. Di Cicco G, Marzano E, Mastrostefano A, et al. The pathogenetic role of RANK/RANKL/OPG signaling in osteoarthritis and related targeted therapies. Biomedicines. 2024;12:2292.
41. Zhu R, Fang H, Wang J, et al. Inflammation as a therapeutic target for osteoarthritis: a literature review of clinical trials. Clin Rheumatol. 2024;43:2417-33.
42. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells. 2019;8:1605.
43. You B, Zhou C, Yang Y. MSC-EVs alleviate osteoarthritis by regulating microenvironmental cells in the articular cavity and maintaining cartilage matrix homeostasis. Ageing Res Rev. 2023;85:101864.
44. Zhou L, Hao Q, Sugita S, et al. Role of CD44 in increasing the potency of mesenchymal stem cell extracellular vesicles by hyaluronic acid in severe pneumonia. Stem Cell Res Ther. 2021;12:293.
45. Jones M, Jones E, Kouroupis D. The use of mesenchymal stem/stromal cell-derived extracellular vesicles in the treatment of osteoarthritis: insights from preclinical studies. Bioengineering. 2024;11:961.
46. Nejad C, Stunden HJ, Gantier MP. A guide to miRNAs in inflammation and innate immune responses. FEBS J. 2018;285:3695-716.
47. Song J, Jin EH, Kim D, Kim KY, Chun CH, Jin EJ. MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. BBA Clin. 2015;3:79-89.
48. Liu H, Chen Y, Huang Y, et al. Macrophage-derived mir-100-5p orchestrates synovial proliferation and inflammation in rheumatoid arthritis through mTOR signaling. J Nanobiotechnology. 2024;22:197.
49. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem. 2012;287:21816-25.
50. Meng F, Li Z, Zhang Z, et al. MicroRNA-193b-3p regulates chondrogenesis and chondrocyte metabolism by targeting HDAC3. Theranostics. 2018;8:2862-83.
